NEW DELHI (Reuters) - India's highest court has dismissed Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms which are increasingly focusing on India to drive sales. In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law. Novartis has been fighting since 2006 to win an Indian patent for an amended form of Glivec. ...
via Health News Headlines - Yahoo! News
Read More Here..
No comments:
Post a Comment